Leah L. Dietrich

777 total citations
18 papers, 524 citations indexed

About

Leah L. Dietrich is a scholar working on Cancer Research, Oncology and Economics and Econometrics. According to data from OpenAlex, Leah L. Dietrich has authored 18 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 8 papers in Oncology and 5 papers in Economics and Econometrics. Recurrent topics in Leah L. Dietrich's work include Breast Cancer Treatment Studies (9 papers), Economic and Financial Impacts of Cancer (5 papers) and Clinical practice guidelines implementation (4 papers). Leah L. Dietrich is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Economic and Financial Impacts of Cancer (5 papers) and Clinical practice guidelines implementation (4 papers). Leah L. Dietrich collaborates with scholars based in United States. Leah L. Dietrich's co-authors include Kathryn J. Ruddy, Jacqueline M. Lafky, Charles L. Loprinzi, Steven Powell, Madhuri Bajaj, Rui Qin, Rudolph M. Navari, Heshan Liu, David D. Biggs and Jeffrey Landercasper and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The American Journal of Surgery.

In The Last Decade

Leah L. Dietrich

16 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leah L. Dietrich United States 11 267 169 142 101 74 18 524
David D. Biggs United States 10 238 0.9× 231 1.4× 137 1.0× 98 1.0× 60 0.8× 20 570
Carlos Carracedo Peru 7 178 0.7× 250 1.5× 77 0.5× 24 0.2× 119 1.6× 13 554
Ioannis‐Georgios Tzanninis Greece 11 68 0.3× 177 1.0× 59 0.4× 96 1.0× 84 1.1× 12 457
Mariangela Bella Italy 7 224 0.8× 180 1.1× 62 0.4× 29 0.3× 55 0.7× 12 491
Massimiliano Salati Italy 12 200 0.7× 394 2.3× 118 0.8× 170 1.7× 62 0.8× 25 743
Cari L. Meinhold United States 9 81 0.3× 207 1.2× 59 0.4× 85 0.8× 29 0.4× 10 483
Niels Kroman Denmark 6 140 0.5× 229 1.4× 39 0.3× 237 2.3× 92 1.2× 8 465
Ki Wook Chung South Korea 13 328 1.2× 152 0.9× 34 0.2× 60 0.6× 34 0.5× 27 634
Felicitas Lenz Germany 6 135 0.5× 196 1.2× 34 0.2× 37 0.4× 73 1.0× 8 421
Andreana N. Holowatyj United States 16 117 0.4× 358 2.1× 33 0.2× 98 1.0× 177 2.4× 45 666

Countries citing papers authored by Leah L. Dietrich

Since Specialization
Citations

This map shows the geographic impact of Leah L. Dietrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leah L. Dietrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leah L. Dietrich more than expected).

Fields of papers citing papers by Leah L. Dietrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leah L. Dietrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leah L. Dietrich. The network helps show where Leah L. Dietrich may publish in the future.

Co-authorship network of co-authors of Leah L. Dietrich

This figure shows the co-authorship network connecting the top 25 collaborators of Leah L. Dietrich. A scholar is included among the top collaborators of Leah L. Dietrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leah L. Dietrich. Leah L. Dietrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Arenz, Andrea, et al.. (2025). The Impact of the COVID-19 Pandemic on the Diagnosis and Treatment of Breast Cancer at a Community Hospital. Clinical Breast Cancer. 25(5). e545–e554.
2.
Landercasper, Jeffrey, Luis D. Ramirez, Andrew J. Borgert, et al.. (2019). A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score–Matched Update From the National Cancer Data Base (NCDB). Clinical Breast Cancer. 19(3). e481–e493. 21 indexed citations
3.
Parsons, Benjamin M., Dipesh Uprety, Angela Smith, Andrew J. Borgert, & Leah L. Dietrich. (2018). A US Registry–Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. 16(11). 1311–1320. 12 indexed citations
4.
Hill, Laura A., Colin Kennedy, Jared H. Linebarger, et al.. (2018). A Strategy for Changing Adherence to National Guidelines for Decreasing Laboratory Testing for Early Breast Cancer Patients.. PubMed. 117(2). 68–72. 4 indexed citations
5.
Landercasper, Jeffrey, Benjamin M. Parsons, Leah L. Dietrich, et al.. (2017). Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database. Annals of Surgical Oncology. 24(6). 1507–1515. 17 indexed citations
6.
Radford, Diane M., Alicia C. Staley, Jeffrey Landercasper, et al.. (2017). What do social media-savvy cancer survivors tell us about the completeness of survivorship care plans?. Journal of Clinical Oncology. 35(15_suppl). 10063–10063.
7.
Navari, Rudolph M., Rui Qin, Kathryn J. Ruddy, et al.. (2016). Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine. 375(2). 134–142. 287 indexed citations
8.
Wisinski, Kari B., Wei Xu, Amyé Tevaarwerk, et al.. (2016). Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer. 16(4). 256–261. 19 indexed citations
9.
Dietrich, Leah L., et al.. (2016). Effectiveness of a Survivorship Program: An Assessment of Patients With Breast Cancer in a Community Setting. Journal of Oncology Practice. 12(6). e688–e696. 7 indexed citations
10.
Parsons, Benjamin M., Jeffrey Landercasper, Angela Smith, et al.. (2016). 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013. Breast Cancer Research and Treatment. 159(2). 315–326. 17 indexed citations
11.
Landercasper, Jeffrey, Jared H. Linebarger, Jeanne M. Johnson, et al.. (2015). Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting. Journal of the National Comprehensive Cancer Network. 13(2). 177–183. 13 indexed citations
12.
13.
Burkard, Mark E., Kari B. Wisinski, Patrick J. Mansky, et al.. (2013). Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer. 14(3). 205–211. 10 indexed citations
14.
Landercasper, Jeffrey, Jared H. Linebarger, Jeanne M. Johnson, et al.. (2012). Prospective synoptic template recording to assess for compliance of care with NCCN guidelines for breast cancer.. Journal of Clinical Oncology. 30(34_suppl). 197–197. 1 indexed citations
15.
Frank, Daniel, Noelle K. LoConte, William R. Schelman, et al.. (2012). A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.. PubMed. 3(2). 90–6. 17 indexed citations
16.
Landercasper, Jeffrey, et al.. (2010). A Community Breast Center Report Card Determined by Participation in the National Quality Measures for Breast Centers Program. The Breast Journal. 16(5). 472–480. 16 indexed citations
17.
Landercasper, Jeffrey, Leah L. Dietrich, & Jeanne M. Johnson. (2006). A Breast Center review of compliance with National Comprehensive Cancer Network Breast Cancer guidelines. The American Journal of Surgery. 192(4). 525–527. 46 indexed citations
18.
Walker, Leslie G., Heidi Schalch, David M. King, et al.. (2005). Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Research. 15(5). 453–459. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David D. Biggs Breakdown of academic impact, for papers by Carlos Carracedo Breakdown of academic impact, for papers by Ioannis‐Georgios Tzanninis Breakdown of academic impact, for papers by Mariangela Bella Breakdown of academic impact, for papers by Massimiliano Salati Breakdown of academic impact, for papers by Cari L. Meinhold Breakdown of academic impact, for papers by Niels Kroman Breakdown of academic impact, for papers by Ki Wook Chung Breakdown of academic impact, for papers by Felicitas Lenz Breakdown of academic impact, for papers by Andreana N. Holowatyj
Rankless by CCL
2026